Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors

被引:4
|
作者
Yi, Min [1 ]
Lin, Heather [2 ]
Bedrosian, Isabelle [1 ]
Shen, Yu [2 ]
Hunt, Kelly K. [1 ]
Chavez-MacGregor, Mariana [3 ,4 ]
King, Tari A. [5 ,6 ]
Mittendorf, Elizabeth A. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
关键词
SURVIVAL; VALIDATION; BURDEN;
D O I
10.1245/s10434-019-07983-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The American Joint Committee on Cancer (AJCC) breast cancer pathological prognostic stage, which incorporates biologic factors, was developed using data from patients undergoing upfront surgery, and its application in patients receiving neoadjuvant chemotherapy (NAC) is unknown. We previously developed the Neo-Bioscore, incorporating clinical and pathological TNM categories with biologic factors, to improve the prognostic stratification of NAC patients. Objective. This study was undertaken to evaluate the use of available staging models incorporating biologic factors in NAC patients. Methods. Patients treated with NAC between 2005 and 2012 at MD Anderson (n = 2363) were staged using the Neo-Bioscore and the AJCC 8th edition: (1) clinical anatomic stage; (2) pathological anatomic stage; (3) clinical prognostic stage; and (4) pathological prognostic stage. Five-year disease-specific survival (DSS) and overall survival (OS) rates, along with Harrell's concordance index (C-index), were estimated. A National Cancer Database (NCDB) cohort (n = 12,887) treated with NAC between 2010 and 2013 was used for validation. Results. In the MD Anderson cohort, staging systems incorporating biologic factors better predicted DSS (bias-corrected C-index: pathological prognostic stage = 0.8026; Neo-Bioscore = 0.7483) and OS (bias-corrected C-index: pathological prognostic stage = 0.7780; Neo-Bioscore = 0.7260) than those using anatomic factors only. Similar results were seen in the NCDB cohort. In pairwise comparisons, the pathological prognostic stage was significantly better (p < 0.0001) than other staging systems in all comparisons except for OS in the NCDB cohort, where it was not significantly different than the Neo-Bioscore (p = 0.2). Conclusion. Biologic factors are important for determining prognosis in patients receiving NAC. These data indicate that the 8th edition AJCC pathological prognostic stage is applicable in these patients.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [31] Factors Predicting Pathological Complete Response and Survival Outcomes in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Louis, Dhanya Mary
    Mathew, Merin
    Gutjahr, Georg
    Mp, Narmada
    Nair, Lakshmi Malavika
    Bhaskaran, Renjitha
    Kottarathil, Vijaykumar Dehannathparambil
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2025,
  • [32] Validation of a novel staging system for breast cancer patients treated with neoadjuvant chemotherapy
    Mittendorf, E. A.
    Tucker, S. L.
    Jeruss, J. S.
    Gonzalez-Angulo, A. M.
    Buchholz, T. A.
    Sahin, A. A.
    Cormier, J. N.
    Buzdar, A. U.
    Hortobagyi, G. N.
    Hunt, K. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Axillary staging prior to neoadjuvant chemotherapy in patients with breast cancer: Predictors of recurrence
    Kilbride, K. E.
    Lee, M. C.
    Nees, A. V.
    Cimmino, A. V.
    Diehl, K. M.
    Sabel, M. S.
    Hayes, D. F.
    Schott, A. F.
    Chang, A. E.
    Newman, L. A.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 : 8 - 8
  • [34] Prognostic factors in breast cancer patients following neoadjuvant chemotherapy
    Kim, JR
    Chang, ES
    BIOMEDICINE & PHARMACOTHERAPY, 2005, 59 : S395 - S396
  • [35] Prognostic factors in breast cancer patients following neoadjuvant chemotherapy
    Kim, J.
    Lee, J.
    Kim, H.
    Chang, E.
    BREAST, 2007, 16 : S29 - S29
  • [36] Prognostic factors for response to neoadjuvant chemotherapy in patients with breast cancer
    Kang, S. Y.
    Jung, Y. S.
    Kim, K. S.
    BREAST, 2011, 20 : S48 - S48
  • [37] Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer
    Bhalla, K
    Harris, WB
    SEMINARS IN ONCOLOGY, 1998, 25 (02) : 19 - 24
  • [38] Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System Review of the Supporting Evidence
    Weiss, Anna
    King, Tari A.
    Hunt, Kelly K.
    Mittendorf, Elizabeth A.
    SURGICAL CLINICS OF NORTH AMERICA, 2018, 98 (04) : 687 - +
  • [39] Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
    Maria D Cao
    Guro F Giskeødegård
    Tone F Bathen
    Beathe Sitter
    Anna Bofin
    Per E Lønning
    Steinar Lundgren
    Ingrid S Gribbestad
    BMC Cancer, 12
  • [40] Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy
    Youzhao Ma
    Minhao Lv
    Peng Yuan
    Xiuchun Chen
    Zhenzhen Liu
    BMC Cancer, 23